The identification of HLA-II neoantigens enables HLA-II neoantigen vaccination and may benefit patients, as CD4+ T cells reactive to the HLA-II neoantigen (KVY15) identified by NESSIE produced IFN-γ and TNFα, suggesting their role in preventing tumor growth. Here, TNF is linked to neoplasm.